Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|January 21, 2021
CPhI China Success Provides Encouragement for 2021 Events and Boon for Industry
Author(s)Pharmaceutical Technology Editors
CPhI China event organizers are encouraged by the success of the recent event and claim that it demonstrates a reassuring return to form for pharma events in 2021, which will also fuel a boom for the industry.
Advertisement
According to a Jan. 20, 2021 press release, CPhI China event organizers are encouraged by the success of the recent event and claim that it demonstrates a reassuring return to form for pharma events in 2021, which will also fuel a boom for the industry.
As reported in the release, the CPhI & P-MEC 2020 event attracted 46,157 visitors, including 5,105 international attendees. Among the companies exhibiting at the show were Pfizer, Sanofi, Capsugel, Dupont, Merck, BASF, Fosun Pharma, Hengrui Medicine, Yangtze River Pharmaceutical, and Fette.
“It was a tremendously successful event for pharma and an encouraging piece of news to start the year with, providing a window into what the post-pandemic exhibition environment can return to,” said Laura Murina, brand manager, Informa, in the press release. “2021 promises to be a celebration of the pharma industry with vaccine distribution now underway and we look forward to helping the industry meet both online and in person so it can continue its work in discovering and delivering vital therapies to patients.”
The 2020 event, which took place on Dec. 16–18, 2020, was a hybrid event comprising online and offline opportunities to learn about the latest industry developments and connect with peers. This year, the organizer has confirmed that the event will take place at the SNIEC between Dec. 16–18, 2021, and will also be a hybrid show.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement